EcuadorTuberculosis profile
Population  2015 16 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.49 (0.41–0.59) 3.1 (2.5–3.6)
Mortality (HIV+TB only) 0.3 (0.13–0.54) 1.9 (0.83–3.3)
Incidence  (includes HIV+TB) 8.4 (5.5–12) 52 (34–75)
Incidence (HIV+TB only) 1 (0.64–1.4) 6.2 (4–9)
Incidence (MDR/RR-TB)** 0.75 (0.45–1) 4.6 (2.8–6.2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.38 (0.18–0.58) 2.7 (1–4.3) 3.1 (1.2–4.9)
Males 0.34 (0.2–0.48) 5 (3.5–6.5) 5.3 (3.7–7)
Total 0.72 (0.46–0.98) 7.7 (5.9–9.5) 8.4 (5.5–12)
TB case notifications, 2015  
Total cases notified 5 215
Total new and relapse 5 097
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 93%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 93%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 60% (42–93)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.1 (0.06–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 545 11%
          - on antiretroviral therapy 472 87%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  370
(300–450)
Estimated % of TB cases with MDR/RR-TB 7.3% (5.4–9.2) 28% (25–31)  
% notified tested for rifampicin resistance 20% 100% 1 950
MDR/RR-TB cases tested for resistance to second-line drugs   59
Laboratory-confirmed cases MDR/RR-TB: 635, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 135, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 77% 5 072
Previously treated cases, excluding relapse, registered in 2014 52% 176
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 45% 132
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 5
Funding source: 22% domestic, 0% international, 78% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data